Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.40 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21982541 | 0.84 | MAPK1 (0.33) | MAPK1MAP2K4MAPK6MAPKAPK2 | |
| SCHEMBL17833922 | 0.82 | MAPK1 (0.35) | MAPK1MAP2K4MAPK6MAPKAPK2 | |
| SCHEMBL19104228 | 0.79 | MAPK1 (0.33) | MAPK1MAP2K4MAPK6MAPKAPK2 | |
| SCHEMBL22328050 | 0.79 | MAPK1 (0.33) | MAPK1MAP2K4MAPK6MAPKAPK2 | |
| SCHEMBL17030758 | 0.79 | MAPK1 (0.33) | MAPK1MAP2K4MAPK6MAPKAPK2 | |
| SCHEMBL19104285 | 0.79 | PDPK1 (0.42) | — | |
| SCHEMBL19104288 | 0.79 | MAP2K4 (0.35) | MAPK1MAP2K4MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL25667658 | 0.78 | MAPK1 (0.40) | MAPK1MAP2K4MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL19104232 | 0.78 | MAPK1 (0.33) | MAPK1MAP2K4MAPK6MAPKAPK2MAPKAPK3 | |
| SCHEMBL22328045 | 0.77 | ADRA2A (0.35) | MAPK1MAP2K4MAPK6MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | ARAXES PHARMA LLC (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-10745385-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | ARAXES PHARMA LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAPK1 898/4885MAP2K4 1832/4885MAPK6 1209/4885 |
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | KRAS, NRAS, HRAS | MAPK1 898/4885MAP2K4 1832/4885MAPK6 1209/4885 |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | KRAS, NRAS, HRAS | MAPK1 473/4885MAP2K4 675/4885MAPK6 2436/4885 |
| US-10745385-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | MAPK1 146/4885MAP2K4 340/4885MAPK6 945/4885 |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | KRAS, NRAS, G3BP2 | MAPK1 100/4885MAP2K4 1046/4885MAPK6 122/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | MAPK1 577/4885MAP2K4 812/4885MAPK6 1224/4885 |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | KRAS, NRAS, HRAS | MAPK1 84/4885MAP2K4 165/4885MAPK6 789/4885 |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | MAPK1 641/4885MAP2K4 369/4885MAPK6 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.